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R E s E A R c h
Report of the NIH Task Force 
on Research Standards for 
Chronic Low Back Pain†
Despite rapidly increasing intervention, func-
tional disability due to chronic low back pain 
(cLBP) has increased in recent decades. We often 
cannot identify mechanisms to explain the major 
negative impact cLBP has on patients’ lives. Such 
cLBP is often termed non-specific, and may be 
due to multiple biologic and behavioral etiologies. 
Researchers use varied inclusion criteria, defini-
tions, baseline assessments, and outcome mea-
sures, which impede comparisons and consensus. 
The NIH Pain Consortium therefore charged a 
Research Task Force (RTF) to draft standards for 
research on cLBP. The resulting multidisciplinary 
panel recommended using 2 questions to define 
cLBP; classifying cLBP by its impact (defined 
by pain intensity, pain interference, and physical 
function); use of a minimal data set to describe 
research participants (drawing heavily on the 
PROMIS methodology); reporting “responder 
analyses” in addition to mean outcome scores; and 
suggestions for future research and dissemination. 
The Pain Consortium has approved the recom-
mendations, which investigators should incorpo-
rate into NIH grant proposals. The RTF believes 
these recommendations will advance the field, 
help to resolve controversies, and facilitate future 
research addressing the genomic, neurologic, and 
other mechanistic substrates of chronic low back 
pain. We expect the RTF recommendations will 
become a dynamic document, and undergo con-
tinual improvement.
Perspective: A Task Force was convened by the 
NIH Pain Consortium, with the goal of develop-
ing research standards for chronic low back pain. 
The results included recommendations for defini-
tions, a minimal dataset, reporting outcomes, and 
future research. Greater consistency in reporting 
should facilitate comparisons among studies and 
the development of phenotypes. 
KEY WORDS: low back pain; chronic low back 
pain; research standards; minimum dataset; NIH 
Task Force
introduCtion 
The Institute of Medicine recently estimated that 
chronic pain affects about 100 million adults in the 
United States, with an estimated annual cost of $635 
billion, including direct medical expenditures and 
loss of work productivity.(3) Activity-limiting low 
back pain (LBP), in particular, has a world-wide 
lifetime prevalence of about 39% and a similar an-
nual prevalence of 38%.(61) The majority of people 
having LBP experience recurrent episodes.(62) The 
use of all interventions for treating chronic LBP 
(cLBP) increased from 1995–2010, including sur-
gery, pharmacological, and non-pharmacological 
approaches. Despite increased utilization, however, 
the prevalence of symptoms and expenditures has 
increased.37,70,91
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Diseases (NIAMS), National Institute of Child Health 
and Human Development, National Institute on Drug 
Abuse, National Institute of Dental and Craniofacial 
Research, National Institute of Neurological Disor-
ders and Stroke (NINDS), and National Institute of 
Nursing Research. The Steering Committee devel-
oped goals for the RTF, identified the needed scientific 
and clinical expertise, selected two co-chairs, and 
invited 14 additional experts from outside NIH to 
comprise the RTF. The Steering Committee provided 
two representatives (Drs. Panagis and Khalsa) in ex-
officio (i.e., non-voting) capacity to the RTF. 
The charge by the NIH Pain Consortium to the RTF 
was to develop a set of standards for clinical research 
on cLBP that would address the following: 
● Consider the state of existing research relevant to 
the development of standards for clinical research 
on cLBP 
● Conduct a comprehensive review of existing 
case definitions, diagnostic criteria, and outcome 
measures that are relevant for clinical research 
on cLBP 
● Develop a draft set of standards for research 
on cLBP 
● Engage the broader research community and 
representatives from relevant government agen-
cies in developing these standards for research 
on cLBP 
● Chart a general plan for their incorporation into 
research studies and their future modification 
This charge focused solely on developing standards 
for research, and not for use in coding, billing, or 
general use in clinical settings.
Methods
Creating the rtf
The Steering Committee selected two co-Chairs 
with complementary leadership expertise. Dr. Deyo 
was chosen for his expertise in LBP research and 
Dr. Dworkin for his prior leadership in developing 
Research Diagnostic Criteria for another chronic pain 
condition, temporomandibular disorders. The co-
Chairs in consultation with the Steering Committee 
selected the RTF members for the needed scientific 
and clinical expertise (Table 1). 
Work plan
The Task Force evolved a three-stage work plan, 
each with a two-day meeting. 
Stage 1
The first meeting opened with remarks by the 
NIAMS and NCCAM Directors, Stephen Katz, 
There is growing evidence that cLBP, like other 
chronic pain conditions, can progress beyond a 
symptomatic state to a complex condition unto 
itself,(109) involving persistent anatomical and func-
tional changes in the central nervous system(9,93,100) 
in addition to structural changes in the back (e.g., 
degenerative spinal changes, atrophy or asymmetry of 
para-spinal muscles).(10,11,14) Although some patients 
with cLBP may have clear pathoanatomic etiologies, 
for many there is no clear association between pain 
and identifiable pathology of the spine or its associ-
ated soft tissues.26
Many patients who undergo procedures intended to 
correct the putative causative pathoanatomy continue 
to have pain. Furthermore, we often cannot identify 
mechanisms to account for the substantial negative 
impact cLBP has on the lives of many patients.(20) 
Such cLBP is often termed non-specific, idiopathic, 
mechanical, or due to instability, and may in fact be 
due to the contributions of different and multiple 
biologic and behavioral etiologies in different indi-
viduals.(87)
Many classes of interventions have been devel-
oped and tested in adults with cLBP. These include 
spine surgery, injections, medications, psychological 
interventions, manual therapies, exercise, nutritional 
supplements, and lifestyle change and self-manage-
ment approaches.(17-20) Many of these have shown 
some clinical benefit, but few appear to consistently 
provide substantial, long-term reductions in pain with 
increased function.(25,27-29) 
A critical issue for advancing research on cLBP 
is comparing results from the many classes of inter-
ventions. In 2009 and 2010, the National Institutes 
of Health (NIH) Pain Consortium convened two 
workshops on LBP research, inviting experts from 
the relevant scientific and clinical fields to provide re-
search recommendations to NIH. These experts noted 
that clinical studies have used variable inclusion and 
exclusion criteria, case definitions for LBP chronic-
ity or recurrence, baseline assessments, stratification 
criteria, and outcome measures. As a result, it is dif-
ficult to compare epidemiological data and studies of 
similar or competing interventions, replicate findings, 
pool data from multiple studies, resolve conflicting 
conclusions, develop multidisciplinary consensus, or 
even achieve consensus within a discipline regarding 
interpretation of findings. Key recommendations from 
the workshops on how to advance cLBP research were 
to establish research standards on cLBP, and to have 
NIH facilitate this process.
In response, the NIH Pain Consortium established 
a Steering Committee for a Research Task Force 
(RTF) on Research Standards for cLBP. The Steer-
ing Committee was comprised of representatives 
from the following NIH institutes/centers: National 
Center for Complementary and Alternative Medicine 
(NCCAM), National Institute on Aging, National 
Institute of Arthritis, Musculoskeletal, and Skin 
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grant applications to NIH, but that the standards 
would be available and encouraged for all research-
ers. The research standards could potentially allow 
cLBP phenotypes to be uncovered, based on physical 
and psychosocial findings.
The RTF decided that it could not respond in 
detail to every component of the NIH Pain Con-
sortium’s charge. For example, producing explicit 
evidence-based diagnostic criteria for conditions 
such as spinal stenosis, sciatica, or spine “instabil-
ity” would be impossible with available time and 
resources, given the current lack of professional 
consensus. However, stratifying cLBP by its im-
pact might have equally important descriptive and 
prognostic value, and could supplement any patho-
physiologic description.
MD, PhD and Josephine Briggs, MD, respectively. 
The directors emphasized the nature of chronic 
back pain as a highly prevalent and costly public 
health challenge. They noted the existence of many 
stakeholders, including individuals with back pain, 
health care systems, clinicians, drug and device mak-
ers, federal, state, third-party payers, and regulatory 
agencies. They emphasized the research focus of 
the Task Force as opposed to a focus on clinical or 
administrative concerns.
Initial efforts of the RTF were directed at defining 
subsequent activities and products. At the initial and 
subsequent meetings, a consensus evolved on several 
important issues and strategies (Table 2). 
The RTF noted that intended users of the proposed 
research standards would be investigators submitting 
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TablE 1. Task Force Members, Affiliations, and Expertise
Members Affiliations Expertise
Co-Chairs
Richard A. Deyo
MD, MPH
Departments of Family Medicine, Internal Medicine, and Public 
Health, Oregon Health and Science University and Clinical 
Investigator, Kaiser Center for Health Research
Primary care, Health Services 
Research
Samuel F. Dworkin
DDS, PhD
Departments of Oral Medicine and Psychiatry and Behavioral 
Sciences, University of Washington
Temporomandibular joint disorders, 
chronic pain, clinical psychology
Task Force Members
Gunnar Andersson
MD, PhD
Department of Orthopaedic Surgery, Rush University Medical 
Center
Orthopaedic spine surgery
David Borenstein MD Department of Rheumatology, George Washington University Rheumatology
Eugene Carragee MD Department of Orthopaedic Surgery, Stanford University School 
of Medicine
Orthopaedic spine surgery
John Carrino MD, 
MPH
Department of Radiology, Johns Hopkins University School of 
Medicine
Musculoskeletal radiology
Roger Chou MD Departments of Medicine, and of Medical Informatics and Clinical 
Epidemiology, Oregon Health and Science University
General Internal Medicine, 
Systematic Review
Anthony DeLitto PT, PhD Department of Physical Therapy, University of Pittsburgh 
School of Health Rehabilitation
Physical Therapy
Christine Goertz DC, PhD Palmer College of Chiropractic Chiropractic care, Epidemiology
John Loeser MD Department of Neurological Surgery, University of Washington Neurosurgery, pain management
Sean Mackey MD, PhD Department of Anesthesia, Stanford University School of 
Medicine
Pain Management, Functional Brain 
Imaging
James Rainville MD Physical Medicine and Rehabilitation, New England Baptist 
Hospital and Tufts University
Spine rehabilitation
Tor Tosteson ScD Department of Community and Family Medicine, Dartmouth 
University
Biostatistics
Dennis Turk PhD Department of Anesthesiology and Pain Medicine, University of 
Washington
Pain medicine, Psychology
Michael Von Korff ScD Group Health Research Institute, Seattle Epidemiology
Debra K. Weiner MD Geriatric Research, Education and Clinical Center, VA Pittsburgh 
Healthcare System and the Departments of Medicine, Psychiatry, 
and Anesthesiology; the Clinical and Translational Science 
Institute, University of Pittsburgh
Geriatric Medicine,
Rheumatology
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on pathophysiologic or etiologic features (i.e., 
criteria for subsets of non-specific cLBP). This 
survey asked Task Force members to assess the 
feasibility of such an effort.
4. Review of Existing Literature on Back Pain 
Classification and Prognosis: The Task Force 
did not undertake a systematic literature review, 
but considered previous work on back pain 
taxonomy,(4,6,15,24,33,34,44,52,56,74,79,83,101,104,105,117) 
prognostic classification,(13,19,31,38,39,43,48,49,53,54, 
57-60,66-68,73,76,80,82,85,86,97,106,108,110,112-116,122) 
pain and psychosocial measures,(12,31,42,45,64, 
65,69,71,75,77,78,81,90,94,96,103,107,115,118-121,125) and 
outcome assessment.(5,8,21,23,32,36,40,41,50,51,55,88,
89,95) This literature informed the deliberations 
and recommendations.
At the second RTF meeting, the most highly ranked 
candidate items for the minimum data set based on 
survey responses were accepted with minimal dis-
agreement or need for further discussion. Special at-
tention was directed to the possible use of the Patient 
Reported Outcomes Measurement Information System 
(PROMIS) measures.(5,21,51,55,89,95) Progress was made 
toward defining cLBP and its impact. There was general 
Stage 2
The co-chairs conducted a series of surveys of 
RTF members by email. The surveys addressed key 
issues from Meeting 1, and were based on item lists 
generated at the first RTF meeting. The surveys and 
literature review efforts were as follows: 
1. Survey of candidate objective findings and 
medical history for a minimal dataset: Mem-
bers ranked the importance of potential base-
line descriptors for patients with cLBP. These 
included items of medical history, comorbidity, 
physical examination, and laboratory and imag-
ing tests.
2. Survey of candidate self-report measures of 
behavior, mood, and symptoms: Task Force 
members were asked to rank the importance of 
measures of pain-related behavioral, emotional 
and psychosocial domains influencing the expres-
sion of cLBP.
3. Survey on Feasibility of Developing Research 
Diagnostic Criteria for subsets of non-specific 
Chronic Low Back Pain: Part of the charge from 
the Pain Consortium was to consider developing a 
Research Diagnostic Classification system based 
TablE 2. Key Principles Developed by the Task Force on Research Standards for Chronic Low Back Pain
1. The process should use an evidence-based approach that incorporates a biopsychosocial model of chronic pain.
2. Data should be useful for a wide range of conditions, including patients thought to have degenerative spinal disorders (e.g. herniated 
disc or lumbar stenosis) as well as those without identified pathoanatomy.
3. Patients with underlying systemic or highly specific diseases were not the target of the Task Force. Such conditions include cancer, 
spinal infections, fractures, and inflammatory spondylopathies such as ankylosing spondylitis.
 
4. Patients with no identified pathoanatomy should not be assumed to have “psychological”, “psychosomatic”, “psychogenic”, or 
“somatoform” pain.
5. Given the current state of knowledge, stratifying chronic back pain by its impact is more feasible and potentially useful than 
attempting classification solely by pathoanatomy or pathophysiology. Impact will tentatively be defined in terms of pain intensity, 
interference with activities, and physical function. 
6. A minimal uniform dataset should be reported in all studies of chronic back pain. This should be brief, so that investigators can 
supplement it with key measures for specific research questions.
7. The dataset should be relevant for population, observational, and interventional research.
8. The dataset should include both biomedical and psychosocial variables.
9. An investigator could substitute more detailed, precise, and well-validated measures for a particular domain, but should report data 
for each domain of the minimal dataset.
10. Additional “core” items would be recommended for specific study aims or populations, such as surgical trials or elderly 
populations.
11. A prognostic dimension for the classification of chronic low back pain would be desirable, but more evidence is needed before an 
explicit recommendation will be made.
12. Research standards should evolve, and the RTF will suggest a potential research agenda for refining the research standards.
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agreement that developing pathophysiologic diagnostic 
criteria for subsets of non-specific low back pain was 
unfeasible at present. 
The RTF also heard presentations of two related 
NIH efforts. The first was the NINDS effort to create 
“Common Data Elements” for use by all Institute-
supported researchers. The second related to the 
NIH PROMIS effort, which includes several psycho-
metrically sound patient reported outcomes measures 
directly relevant to the Task Force.
Stage 3
At the third meeting, the RTF agreed on a series 
of recommendations to be forwarded to the NIH Pain 
Consortium. These included a definition of cLBP and 
specific measures to stratify its impact. It also reached 
agreement on recommending specific domains and 
items to be integrated into a minimal dataset for 
research on cLBP. There followed a discussion of 
outcome measures and future research needs regard-
ing the Task Force recommendations. 
The Task Force also suggested strategies for 
obtaining feedback and support for its recommen-
dations. These included consultation with the NIH 
Pain Consortium and relevant NIH institutes, other 
government agencies, and relevant journal editors. 
It would also include presentations at meetings of 
research and professional organizations.
tAsK forCe reCoMMendAtions
The principles articulated in Table 2 led the Task 
Force to several specific recommendations that are 
summarized in Table 3. The rationales for these rec-
ommendations are discussed below. The first three 
recommendations refer to the questionnaire instru-
ment in Table 4. 
recommendation 1. describe the Chronicity of 
low back pain
The RTF recommended that “chronic low back 
pain ” (cLBP) be defined as a back pain problem 
that has persisted at least 3 months, and has resulted 
in pain on at least half the days in the past 6 months. 
A human figure drawing would illustrate the region 
defined as the low back, indicating the space between 
the lower posterior margin of the rib cage and the 
horizontal gluteal fold (Table 4).
The RTF considered definitions based on time with 
pain, days with pain, severity of pain, and varying 
durations of pain. Minimal durations of 3 months 
or 6 months were considered, and the problem of 
intermittent symptoms was considered.
The RTF concluded that two questions should 
define chronicity (Questions 1 and 2 in Table 4): 
(1) “How long has back pain has been an ongoing 
TablE 3. Task Force Recommendations: Research Standards for Chronic Low Back Pain (cLBP)
1. Defining the chronicity of cLBP: The RTF recommended 2 questions to achieve the definition of chronic (Questions 1 and 2 in Table 
4): (1) How long has back pain has been an ongoing problem for you? (2) How often has low-back pain been an ongoing problem for 
you over the past 6 months? A response of greater than three months to question 1, and a response of “at least half the days in the past 
6 months” to question 2 would define cLBP. 
2. Stratify cLBP by impact: “Impact” was defined by pain intensity, pain interference with normal activities, and functional status. These 
items have major prognostic and discriminatory importance. Impact is calculated from 9 items of the 29-item PROMIS short form 
(marked with asterisks in Table 4).
3. Report a Minimum Data Set: A minimal data set is recommended for describing subjects in all research on cLBP (Table 4). 
Medical history included demographics, involvement in workers compensation, work status, education, comorbidity, and previous 
treatment. Physical examination items were reserved for studies of invasive interventions or of older adults. MRI was recommended 
for studies of surgical interventions. Key self-report domains were pain intensity, pain interference, physical function, depression, 
sleep disturbance, and catastrophizing. The short form PROMIS measures were recommended as offering the best trade-off of length 
with psychometric validity. 
4. Outcome Measures: Many parts of the minimum data set, such as PROMIS measures, are also appropriate as outcome measures. 
However, primary outcomes of clinical studies will vary, depending on study aims, and investigators are referred to earlier consensus 
documents on outcome measures. The RTF recommended reporting a “responder” analysis in addition to reporting mean scores of 
outcome measures.
5. Research on the proposed standards The RTF recommended new research to improve prognostic stratification of patients 
with chronic low back pain; refine and test composite outcome measures for increasing the clinical importance of study 
results; undertake patient stakeholder assessment of relevant outcomes; and further evaluate psychometric properties of the 
minimal dataset. 
6. Dissemination: With adoption of recommendations by the NIH Pain Consortium, the RTF recommends dissemination to the broad 
research community. This would include publication of a report in multiple professional journals and presentations at professional 
meetings.
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TablE 4. Recommended Minimum Dataset
(PROMIS items marked with 1; STarT Back or nearly identical items marked with 2; RTF Impact Classification items marked with *).
1. How long has low-back pain been an ongoing problem for you?  
	Less than 1 month
	1–3 months
	3–6 months
	6 months–1 year
	1–5 years
	More than 5 years
2. How often has low-back pain been an ongoing problem for you over the past 6 months? 
	Every day or nearly every day in the past 6 months
	At least half the days in the past 6 months
	Less than half the days in the past 6 months 
3. In the past 7 days, how would you rate your low-back pain on average?*1,2

1

2

3

4

5

6

7

8

9

10
No pain Worst
Imaginable
pain
4. Has back pain spread down your leg(s) during the past 2 weeks?2
	Yes
	No
	Not sure
5. During the past 4 weeks, how much have 
you been bothered by … Not bothered at all Bothered a little Bothered a lot
• Stomach pain   
• Pain in your arms, legs, or joints other 
than your spine or back   
• Headaches   
• Widespread pain or pain in most of 
your body   
6. Have you ever had a low-back operation? 
	Yes, one operation
	Yes, more than one operation
	No 
7. If yes, when was your last back operation? 
	Less than 6 months ago 
	More than 6 months but less than 1 year ago 
	Between 1 and 2 years ago 
	More than 2 years ago 
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8. Did any of your back operations involve a spinal fusion? (also called an arthrodesis) 
	Yes 
	No 
	Not sure
PAIN INTERFERENCE
In the past 7 days… Not at all A little bit Somewhat Quite a bit Very much
9. How much did pain interfere with 
your day-to-day activities?*1     
10. How much did pain interfere with 
work around the home?*1     
11. How much did pain interfere with 
your ability to participate in social 
activities?*1
    
12. How much did pain interfere with 
your household chores?*1     
13. Have you used any of the following treatments for your back pain? (Check all that apply)
Yes No Not sure
• Opioid painkillers (prescription medications such as Vicodin, Lortab, 
Norco, hydrocodone, codeine, Tylenol #3 or #4, Fentanyl, Duragesic, 
MS Contin, Percocet, Tylox, OxyContin, oxycodone, methadone, tramadol, 
Ultram, Dilaudid)
  
If you checked yes, are you currently using this medication?………………………….  
• Injections (such as epidural steroid injections, facet injections) 
……………..   
• Exercise therapy………………………………………………………………   
• Psychological counseling, such as cognitive-behavioral therapy……………   
The next two questions are for people who normally work outside the home.
14. I have been off work or unemployed for 1 month or more due to low-back pain. 
	Agree 
	Disagree 
	Does not apply
15. I receive or have applied for disability or workers’ compensation benefits because I am unable to work due to 
low-back pain.
	Agree 
	Disagree 
	Does not apply 
PHYSICAL FUNCTION
Physical Function Without any 
difficulty
With a little 
difficulty
With some 
difficulty
With much 
difficulty
Unable  
to do
16. Are you able to do chores such 
as vacuuming or yard work?*1     
17. Are you able to go up and down 
stairs at a normal pace?*1     
18. Are you able to go for a walk of 
at least 15 minutes?*1,2     
19. Are you able to run errands 
and shop?*1     
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
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DEPRESSION
In the past 7 days... Never Rarely Sometimes Often Always
20. I felt worthless1     
21. I felt helpless1     
22. I felt depressed1     
23. I felt hopeless1     
SLEEP DISTURBANCE
In the past 7 days… Very poor Poor Fair Good Very good
24. My sleep quality was1     
In the past 7 days… Not at all A little bit Somewhat Quite a bit Very much
25. My sleep was refreshing1     
26. I had a problem with my sleep1     
27. I had difficulty falling asleep1     
28. It’s not really safe for a person with my back problem to be physically active.2 
	Agree
	Disagree 
29. I feel that my back pain is terrible and it’s never going to get any better.2 
	Agree
	Disagree 
30. Are you involved in a lawsuit or legal claim related to your back problem? 
	Yes 
	No 
	Not sure
In the past year: 
Never Rarely Sometimes Often
31. Have you drunk or used drugs more than you meant to?    
32. Have you felt you wanted or needed to cut down on your 
drinking or drug use?    
33. Age: _____ years (0–120) 
34. Gender: 
	Female 
	Male 
	Unknown 
	Unspecified 
35. Ethnicity: (“X” ONLY one with which you MOST CLOSELY identify) 
	Hispanic or Latino 
	Not Hispanic or Latino 
	Unknown
	Not Reported
36. Race: (“X” those with which you identify)
	American Indian or Alaska Native
	Asian
	Black or African-American
	Native Hawaiian or Other Pacific Islander
	White
	Unknown
	Not Reported
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
24
InternatIonal Journal of therapeutIc Massage and Bodywork—VoluMe 8, nuMBer 3, septeMBer 2015
37. Employment Status:
	Working now
	Looking for work, unemployed
	Sick leave or maternity leave
	Disabled due to back pain, permanently or temporarily
	Disabled for reasons other than back pain 
	Student
	Temporarily laid off 
	Retired
	Keeping house 
	Other, Specify:_________________
	Unknown
38. Education Level: (select the highest level attained)
	No high school diploma
	High school graduate or GED
	Some college, no degree
	Occupational/technical/vocational program
	Associate degree: academic program
	Bachelor’s degree
	Master’s degree (e.g., M.A., M.S., M.Eng., M.Ed., M.B.A.)
	Professional school degree (e.g., M.D., D.D.S., D.V.M., J.D.)
	Doctoral degree (e.g., Ph.D., Ed.D.)
	Unknown
39. How would you describe your cigarette smoking?
	Never smoked
	Current smoker
	Used to smoke, but have now quit
40. Height: _____  inches  centimeters  measured  self-reported
Weight: ____  pounds  kilograms  measured  self-reported
problem for you?” (2) “How often has low-back 
pain been an ongoing problem for you over the past 
6 months?” A response of greater than three months 
to question 1, and a response of “at least half the 
days in the past 6 months” to question 2 would define 
cLBP. A patient with pain on at least half the days in 
the past 6 months would have accumulated at least 
three months worth of pain days, and the Task Force 
concluded that this would be the recommended defini-
tion. It was decided that pain severity would not be 
part of the definition of cLBP.
recommendation 2. stratify chronic low back 
pain by impact
“Impact” was defined by pain intensity, pain inter-
ference with normal activities, and functional status, 
using nine items of the 29-item PROMIS short form 
(marked with asterisks in Table 4).
The RTF overwhelmingly agreed that neither ade-
quate data nor resources were available to offer a new 
pathoanatomic or pathophysiologic subclassification 
of cLBP that was clearly superior to those currently 
available. Rather, the RTF recommended stratification 
of cLBP by the personal impact of low back pain. 
“Impact” was proposed as a combination of pain 
intensity, pain interference with normal activities, 
and functional status. These items have substantial 
research support to validate their discriminatory and 
prognostic importance.(13,19,31,38,39,43,47-49,53,54,57-60,66-
68,73,76,80,82,85,86,97,106,108,110,112-116,122) 
This stratification of cLBP by impact would be 
appropriate whether or not there appears to be con-
tributory degenerative pathoanatomy. Even when 
pathoanatomic conditions are thought to contribute 
to symptoms and dysfunction, they often coexist and 
overlap, and sometimes fail to respond to specific 
interventions. Thus, the stratification of impact seems 
to be a useful addition to pathoanatomic, physiologic, 
or symptomatic classification, but not a substitute.
After considerable discussion about formal prog-
nostic scales for stratification, such as the Subgroups 
for Targeted Treatment (STarT) Back instrument,(60) 
the RTF decided there remained substantial uncer-
tainty about generalizability to subspecialty patients 
and older adults. Thus, the RTF recommended 
further research in this area, and included several 
items of the STarT Back instrument in the minimal 
dataset, but chose not to require them for stratifica-
tion purposes. 
The recommended RTF Impact Stratification ap-
proach uses the raw PROMIS scores with the usual 
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more advanced degree, and 5% with less than a high 
school diploma.
The data set included legacy measures of back 
pain-related physical function: the Roland and Mor-
ris Disability Scale and the Oswestry Disability 
Index (collected at baseline only). The RTF Impact 
Stratification showed strong correlations with legacy 
measures. Furthermore, score changes on the RTF 
Impact Stratification correlated more strongly with 
patient satisfaction at follow-up than did change on 
the Roland-Morris score (Table 5). 
In this rather severely affected sample, baseline 
RTF Impact scores were almost equally distributed 
among mild, moderate and severe impacts. Al-
though the cutoffs used in Table 5 for mild, moder-
ate, and severe scores were deemed as potentially 
useful by the RTF, they are relatively arbitrary. 
Simply reporting actual scores is recommended, 
along with any categorization that investigators 
may choose. 
Scores on the Impact Stratification measure for this 
sample improved over time, as expected. Measures 
of effect size and standardized response mean for the 
170 patients available for 3-month follow-up sug-
gested that the RTF Impact Stratification was more 
responsive than the Roland-Morris Disability Scale 
(Table 3).
The Task Force found the results encouraging but 
acknowledges that the analyses reported reflect only 
scoring of the Physical Function items is reversed. 
Thus, for each item in the Impact Stratification, a 
score of 1 is least severe and 5 most severe. The 
exception is the single item on pain intensity, which 
ranges from 0 (least severe) to 10 (most severe). Thus, 
scores on the nine PROMIS-based items yielding 
Impact Stratification range from 8 (least impact) to 
50 (greatest impact). Items in Table 4 with an asterisk 
comprise the Impact Stratification score. 
Because the proposed impact score is a novel com-
bination of three constructs (pain intensity, interfer-
ence, and function), the RTF undertook a preliminary 
assessment of its validity and performance, with the 
assistance of PROMIS investigators. The validation 
made use of existing PROMIS data from a group 
of patients with LBP, with or without leg pain, who 
underwent epidural steroid injections. This analysis 
was covered by an existing Institutional Review 
Board approval from the University of Washington. 
Given the intervention, an improvement in average 
functional scores was expected. 
The sample included 218 patients with a mean 
age of 54 years; 56% were females. There were 41% 
employed full or part time, 22% retired, and 12% 
receiving disability compensation, with the remain-
der being homemakers, students, or unemployed. 
The racial mix included 87% white, 3.8% African 
American, 4% American Indian, and 5% Asian or 
Pacific Islander. There were 46% with a college or 
TablE 5. Performance of the Research Task Force Impact Stratification Among 218 Subjects Undergoing Epidural Steroid Injections; 
Three-Month Follow-Up Was Available for 170 of These Subjects (78%)
Construct validation: correlation of RTF Impact Stratification with 
Legacy measures of physical function, baseline (Spearman R)
Oswestry Disability Index Roland-Morris Disability 
Questionnaire
RTF Impact Stratification score .806 .661
Construct validation: correlation of score changes with patient 
satisfaction with treatment at follow-up (Spearman R, absolute value)
Change, Roland- Morris Disability 
Questionnaire
Change, RTF Impact 
Stratification score
Patient satisfaction index, scored 1-4 .148 .251
Distribution of RTF Impact Stratification scores Baseline (N=218),
% of subjects
Follow-up (N=170),
% of subjects
RTF Impact stratification score 8-27 (mild) 30% 63%
RTF Impact stratification score 38-34 (moderate) 34% 18%
RTF Impact stratification score ≥35 (severe) 36% 19%
Mean RTF Impact stratification score (SD) 32 (8.3) 25 (9.7)
Responsiveness Effect Size  
(Change/Baseline SD)
Standardized Response Mean  
(Change/SD of change)
RTF Impact Stratification 0.69 0.75
Roland-Morris Disability Questionnaire 0.39 0.41
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catastrophizing. The Task Force felt these constructs 
were important for a wide range of patients with 
chronic back pain, with or without specific patho-
anatomic diagnoses. For parsimony, other important 
constructs, such as anxiety, fatigue, and satisfaction 
with social role were considered, but not included in 
the minimal data set.
Although the Minimal Dataset in Table 4 is rec-
ommended for inclusion in all NIH-funded research 
on cLBP and is available for use by all research-
ers, the RTF did not in any way intend to constrain 
investigators regarding the scope of their proposed 
scientific inquiries. On the contrary, the RTF believes 
the minimal data set represents a major advance to-
wards standardization of research reporting by asking 
researchers to include, at a minimum, a set of items 
that evidence supports as critical to scientifically 
advancing our understanding of cLBP. 
After considering several potential instruments 
for assessing these domains, the RTF concluded that 
the short-form PROMIS measures(1) offered the best 
trade-off of length with psychometric validity for 
a minimal dataset. Therefore, it recommended use 
of the relevant scales from the 29-item PROMIS 
short-form, which includes 4 items for each domain. 
Investigators and patient samples with access to Com-
puter Adaptive Testing could use the entire PROMIS 
item bank to measure the domains included on the 
PROMIS 29 Profile version 1.0, an acceptable or even 
preferable alternative.(22) 
There was agreement that if investigators preferred 
well-validated, lengthier legacy measures of these 
domains, that would be acceptable. For example, if 
investigators wanted more extensive legacy mea-
sures of physical function, they might substitute the 
Oswestry or Roland-Morris disability scales for the 
PROMIS physical function items. If they wanted 
legacy measures of depression, they might substitute 
the Patient Health Questionnaire (PHQ-9)(76) or Beck 
Depression Inventory.(12) In Table 4, we have labeled 
the PROMIS constructs to facilitate such substitution 
if desired, though investigators may wish to remove 
the labels when using the dataset. If such substitutions 
are made, all the other recommended domains should 
still be assessed.
Investigators may find it useful to consult the 
website PROsetta Stone, supported by NCI-funded in-
vestigators at Northwestern University (www.proset-
tastone.org).(2) This website provides a “cross-walk” 
between scores on the PROMIS measures and scores 
on several “legacy” measures, such as the Brief Pain 
Inventory,(31) the Center for Epidemiologic Studies 
Depression Scale (CES-D),(90) the PHQ-9,(77) and the 
SF-36.(120) The resulting proposed Minimal Dataset 
is presented in Table 4. PROMIS items are identified 
with a superscript 1, and STarT Back items (or very 
similar items) are identified with a superscript 2. 
The RTF was able to obtain IRB approval at 
Stanford University (RTF member Sean Mackay, 
an initial assessment. As suggested in the recommen-
dations below for future research, further assessment 
of the reliability, validity and clinical utility of this 
stratification strategy is a high priority. 
recommendation 3. report a Minimum dataset
A minimal data set is recommended for describing 
individuals participating in all research studies on 
cLBP (Table 4); the minimum data set includes items 
of demographics, medical history, and self-report of 
symptoms and function.
Medical history, physical examination, 
diagnostic testing
In the survey of RTF members regarding items for a 
minimal dataset, the most highly ranked items of medi-
cal history and examination included demographics, 
involvement in workers’ compensation or legal claims, 
work status, education, various measures of comorbid-
ity, and previous treatment history. For many of these 
measures, the RTF adopted the format of the Common 
Data Elements system implemented by the NINDS 
(http://www.commondataelements.ninds.nih.gov). 
The key comorbid conditions were judged to be 
smoking status, obesity, substance abuse, and wide-
spread pain symptoms. The two-item conjoint scale 
(TICS) was judged to be an adequate and suitably 
brief screen for substance abuse.(18) The key items 
of treatment history were thought to be history of 
surgical interventions and use of opioid analgesics. 
Measures from the physical examination ranked 
lower than items of medical history. However, the 
most highly ranked of these were straight leg raising 
for patients with leg pain; hip internal rotation as a 
screen for hip arthritis (a potential cause of LBP); and 
lower extremity strength. There was general agree-
ment that such physical examination items could be 
reserved for studies of invasive interventions (straight 
leg raising and lower extremity strength) or of older 
adults (hip examination). Thus, physical examination 
measures would not be required of all epidemiological 
studies, for example. 
No laboratory or imaging tests were highly ranked, 
because of the widely recognized weak association 
between degenerative spine changes on imaging and 
patient symptoms or function.(26) However, magnetic 
resonance imaging (MRI) was considered the most 
valuable of potential tests, and there was agreement 
that this should be required in studies of surgical 
interventions.
Self-report of functional status, psychosocial 
factors, and mood disturbance
With regard to other self-report measures, there 
was discussion first about the domains to be included, 
then potential sources of items, then the desirable 
number of items. The key domains were judged to be 
physical function, depression, sleep disturbance, and 
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recommends reporting a “responder” analysis in ad-
dition to reporting mean scores of outcome measures.
The RTF recognized that many parts of the baseline 
minimum data set, such as the PROMIS measures, 
were highly appropriate as outcome measures, re-
membering that the initial focus of the NIH PROMIS 
effort was on patient reported outcomes. It was also 
recognized that the primary outcomes of clinical stud-
ies would vary, depending on study aims. For exam-
ple, some might focus on pain relief, but others might 
focus on return to work, physical function, mood, or 
need for subsequent therapy. Thus, the RTF did not 
make a recommendation regarding a minimal out-
come dataset, beyond recommending consideration 
of the minimal data set for standardized recording of 
both baseline assessment and outcomes evaluation. 
Investigators are referred to earlier consensus state-
ments on outcome measures for studying chronic pain 
in general or back pain in particular.(16,35,40) 
Reporting of outcomes
An important discussion centered on reporting of 
outcomes. There was a general agreement that for (at 
least theoretically) continuous measures, such as pain 
or function, not only should mean scores and score 
changes be reported, but the proportion of participants 
achieving certain thresholds should be reported. For 
example, the proportion achieving a pre-specified 
minimal clinically important change might be report-
ed. Investigators have proposed minimally important 
differences in PROMIS short forms, at least in the 
context of cancer therapy.(123) Calculating the percent 
of study participants who achieve such landmarks is 
referred to by the FDA as a “responder” analysis.(84) 
Other expert panels have suggested, for example, 
that a 30% improvement in pain or function might be 
a clinically important difference, and recommended 
reporting the proportion of participants with this 
degree of improvement.(46) Statistical analysts have 
suggested potential problems with the use of percent-
age changes,(111) but the approach has clinical appeal. 
One might alternatively specify a certain number of 
points as the relevant change, or the percentage of 
participants reaching some threshold pain level (e.g., 
pain score less than 3 out of 10).
An attractive option to the RTF was reporting the 
“cumulative distribution function” of responses for 
the treatment and control group. This is a continuous 
plot of the proportion of patients at each scale score 
who experience change at that level or better. This 
amounts to calculating the percentage of responders 
at each value of the outcome score. This approach 
acknowledges the lack of consensus on the approach 
for establishing a responder threshold, and provides 
information for any given threshold.(84) 
Composite outcome measures
The RTF also discussed the potential for use of 
composite outcome measures. One member noted 
Principal Investigator) to conduct an internet survey 
of back pain patients using the RTF recommended 
version of the Minimal Dataset. This cross-sectional 
sample was distinct from the patients described 
above for validity testing, who underwent interven-
tion and follow-up. There were 221 participants 
recruited from the San Francisco Bay Area using 
high-visibility ads. Participants had a mean age of 
46.2 years (range, 19-81), with 53% females. Partici-
pants included 72% whites; 17% Asians; 7% African 
Americans, and 3.8% each of American Indians and 
Pacific Islanders. There were 52% with at least a 
bachelor’s degree and only a single participant with 
no high school diploma. Thirty-nine percent were 
employed, 5% retired, and 16% described them-
selves as disabled. Thirty-eight percent described 
leg pain in addition to back pain, and the mean pain 
intensity (on a 0-10 scale) was 5.5. In this sample, 
the median time-to-completion was 7 minutes, and 
75% of subjects completed the questionnaire in less 
than 10 minutes. 
Proposed supplemental data for specific 
situations
For studies of invasive therapies such as spine 
surgery, the RTF recommended that physical exami-
nation and imaging data be added to the minimal data 
set. Straight leg raising, lower extremity reflexes, 
and lower extremity strength as indicators of radicu-
lopathy were recommended as a minimum physical 
examination. Lumbar MRI was recommended in such 
studies as the minimal imaging evaluation.
In older adults, there is increased likelihood of hip 
osteoarthritis contributing to low back pain. Thus, for 
studies of adults mainly over age 65, the Task force 
recommended testing internal hip rotation, to help 
screen for potential osteoarthritis. A screen for cogni-
tive function may also be important in such studies, 
as dementia may impair the validity of assessments 
or of consent for research. 
In studies focused on behavioral or mood correlates 
of cLBP, the RTF recommended that investigators 
be free to incorporate additional measures. These 
might include, for example, assessment of emotional 
status, physical function and pain behaviors, sub-
stance abuse, interpersonal violence, or quality of life 
relevant to specific study interests. Such measures 
should have published reliability, validity, and respon-
siveness data at least equal to those of the minimal 
dataset’s PROMIS short-form items. These additional 
measures should have population-based normative 
data to be included when relevant. The IMMPACT 
statement can be recommended as a starting point for 
selection of desired supplemental measures.(9)
recommendation 4. outcome measures
Investigators are referred to earlier consensus docu-
ments on outcome measures.(16,35,40) However, the RTF 
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recommendations. The potential for such an itera-
tive approach to re-evaluate scientific measures of 
chronic pain was successfully modeled in developing 
Research Diagnostic Criteria for Temporomandibular 
Disorders (TMD). An iterative scientific process has 
successfully evolved the next generation of evidence-
based measures for diagnosing and classifying the 
most common subtypes of TMD, including physical, 
behavioral and psychosocial domains.(99) 
Beyond viewing the present set of recommenda-
tions as appropriate topics for future research, the RTF 
identified several related knowledge gaps that limit 
our ability to define and classify critical domains and 
variables. These were seen as important topics for 
which further research should be encouraged.
Prognosis
Improving prognostic stratification of patients 
with cLBP is important clinically to help guide the 
nature and intensity of therapy, and important for 
researchers to adjust for confounding and to improve 
comparability among studies. Recent work such as the 
STarT Back project from the U.K. has made important 
advances in this regard,(57-60) and others have system-
atically reviewed risk factors for the emergence of 
chronic back pain.(30) However, the generalizability of 
such studies to interventions and populations outside 
of primary care remain uncertain. Other approaches 
may be important for specific populations, or predict-
ing specific treatment outcomes. Additional work in 
this area might improve the ability to characterize 
clinically important subgroups of patients with cLBP 
and improve our “impact stratification”.
Composite outcome measures
An ongoing frustration has been the seeming lack 
of progress in reducing back-related disability at 
a population level. In part, this may be a result of 
claiming treatment efficacy based on statistically 
significant but clinically trivial results. More work is 
needed to understand how certain outcome scores are 
associated with major events such as return to work. 
Composite outcome measures, such as requiring si-
multaneous improvement in pain, function, and global 
self-assessment, may move us closer to important out-
comes. However, more data are needed to determine 
the performance of such measures in terms of validity, 
reliability, responsiveness, and prognostic value.
Patient stakeholder assessment
Little work has addressed the outcomes judged 
most important by patients with chronic low back 
pain. Such outcomes may vary with demographic 
features and diagnosis. 
Psychometric properties of the proposed 
minimal dataset
Extensive effort has been made to validate the PRO-
MIS measures,(5,7,21,51,55,72,89,92,95) but there is modest 
that it is common in studies of osteoarthritis to require 
improvement in pain score and functional status and 
global self-assessment before judging treatment suc-
cessful. Similar combinations have been proposed for 
evaluating back pain.(17,102)
Composite measures are often required in FDA 
trials for drug or device approval. For example, “suc-
cess” in trials of artificial disc replacement required 
functional improvement of 15 points on the Oswestry 
scale, improvement in quality of life on the SF-36, 
proper radiographic placement, and absence of new 
neurologic deficits or revision surgery.(124) Such 
composites offer the potential advantage of defining 
success in terms that are clearly clinically important, 
and not merely statistically significant. 
However, the RTF concluded that with the paucity 
of data on performance of such composite measures 
for low back pain, it could not make a recommendation 
about composite outcome measures. Instead, this was 
recommended as an important topic for future research. 
Time frames for outcome measures
The RTF chose not to make specific recommen-
dations for timing of outcome assessments because 
appropriate timing would vary depending on an 
intervention. For some treatments (e.g., analgesics 
or spinal manipulation), the goal may be short-term 
relief. For others, such as surgery, the goal is more 
often long-term relief. For studying patients with 
chronic pain, longer-term follow-up (e.g., at least 
6-12 months) is generally preferred. 
Adverse events
Reporting of adverse events was recognized as 
an important outcome measure. Because the likely 
adverse events vary enormously with the nature of 
an intervention, the RTF did not make recommenda-
tions for reporting specific adverse events. There was 
general agreement that for most intervention studies, 
it would be desirable to specify certain adverse events 
in advance and measure them prospectively, along 
with open-ended reporting of unanticipated events. 
recommendation 5. research on the proposed 
standards
The RTF recommended new research to improve 
prognostic stratification of patients with cLBP; refine 
and test composite outcome measures for increasing 
the clinical importance of study results; undertake 
patient stakeholder assessment of relevant outcomes; 
and further evaluate psychometric properties of the 
minimal dataset.
Because the measures in the minimal dataset 
will often not comprise the sole measures used in 
a study, their widespread use will not only provide 
researchers a standardized set of data, but will also 
provide accumulating evidence for (or against) the 
reliability, validity, and clinical utility of the RTF 
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defined Research Diagnostic Criteria for subsets of 
cLBP. While creation of research diagnostic criteria 
has proven beneficial to research for some other con-
ditions (e.g., temporomandibular joint disorders,(99) 
Alzheimer’s Disease(98)), the multifactorial nature of 
most cases of cLBP decreased enthusiasm for attempt-
ing to do so in this condition. However, creation of an 
impact stratification and a uniform minimal dataset 
will achieve many of the same goals.
In summary, the RTF has recommended a definition 
of cLBP and proposed classifying it in terms of its 
impact, in addition to any presumed pathoanatomic di-
agnosis. Impact is conceived as a combination of pain 
intensity, interference with activities, and physical 
function. The RTF has also recommended a uniform 
minimal data set, with recommendations for medical 
history, physical examination, diagnostic tests, and 
self-report measures of physical function, depression, 
and sleep disturbance, in addition to pain intensity 
and interference. Finally, recommendations have been 
made for reporting patient outcomes, further research, 
and dissemination of the recommendations.
Any effort to standardize research methods is only 
a starting point for further testing and refinement. 
The final recommendations were seen as a first step 
towards creating Standards for Research in cLBP. We 
anticipate that further validation, refinement, and pos-
sible extension of these recommendations will require 
years and the efforts of many investigators. Nonethe-
less, the RTF believes these recommendations can 
advance the field, help to resolve controversies, and 
facilitate future research addressing the prevalence 
and incidence and genomic, neurologic, and other 
mechanistic substrates of cLBP. Furthermore, it can 
help to reveal the biologic-behavioral interfaces that 
confound our present day understanding of cLBP and 
its evidence-based management. 
It is anticipated that the RTF recommendations will 
become a dynamic document, and that the proposals 
are likely to undergo continual improvement. The pro-
posed research agenda should facilitate this evolution.
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information on their performance specifically in the 
context of cLBP. One recent study suggested excellent 
performance of the PROMIS physical function item 
bank among patients with back and neck problems.(63) 
Further data on the precision of the domains is impor-
tant (e.g., the optimal number of items), as well as data 
on responsiveness to change and sensitivity to small 
differences. Creating a “cross-walk” of scores with 
legacy measures such as the Oswestry and Roland-
Morris disability questionnaires is also important.
recommendation 6. dissemination of the 
report of the nih task force on research 
standards for Chronic low Back pain
With adoption of recommendations by the NIH 
Pain Consortium, the RTF recommends dissemination 
to the broad research community, including publica-
tion of a report in multiple professional journals and 
presentations at professional meetings.
The NIH Pain Consortium has accepted the RTF 
report (to view the full NIH approved RTF report on 
Standards for Research on Chronic Low back Pain see: 
www.painconsortium.nih.gov). The consortium is rec-
ommending that all NIH institutes and centers require 
grant applications proposing clinical studies of cLBP 
to utilize the research standards set forth in the RTF 
report. Similarly, NIH encourages all other agencies 
that fund research on cLBP to consider incorporating 
these research standards for their respective awardees 
or investigators, as appropriate. The RTF proposed to 
disseminate these recommendations in professional 
journals and presentations at scientific meetings.
disCussion
Consistent with its charge from NIH, the RTF 
strove to recommend standards for conducting re-
search into the complex, intertwined factors that 
influence the onset, natural history and clinical course 
of cLBP. This remains one of the most important and 
costly of all public health conditions affecting the U.S. 
population. As adopted by NIH, these recommenda-
tions have the potential to standardize methods for 
identifying cLBP research cases, describing research 
subjects, and comparing published reports.
The new research standards should improve the 
comparability of research studies on cLBP, facilitate 
pooling data from multiple studies (e.g., for meta-
analyses), and improve the ability to define phe-
notypes among patients with low back pain. These 
standards will allow comparable core summary 
statistics to be included in all published reports, with-
out interfering with collection of specific measures 
needed to address specific research questions.
After extended review and discussion, the RTF con-
cluded that at the current state of scientific evidence 
on cLBP, it was not realistic to create operationally 
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
30
InternatIonal Journal of therapeutIc Massage and Bodywork—VoluMe 8, nuMBer 3, septeMBer 2015
index for patients with chronic low back pain. J Rheumatol. 
2011;38:362–369.
18. Brown RL, Leonard T, Saunders LA, Papasouliotis O. A two-
item conjoint screen for alcohol and other drug problems. J Am 
Board Fam Pract. 2001;14:95–106.
19. Bruyere O, Demoulin M, Brereton C, Humblet F, Flynn D, Hill 
JC, et al. Translation validation of a new back pain screening 
questionnaire (the STarT Back Screening Tool) in French. Arch 
Public Health. 2012;70:12.
20. Bunzli S, Watkins R, Smith A, Schutze R, O’Sullivan P. Lives 
on hold: a qualitative synthesis exploring the experience of 
chronic low-back pain. Clin J Pain. 2013;29:907–916.
21. Buysse DJ, Yu L, Moul DE, Germain A, Stover A, Dodds NE, 
et al. Development and validation of patient-reported outcome 
measures for sleep disturbance and sleep-related impairments. 
Sleep. 2010;33:781–792.
22. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et 
al. The Patient-Reported Outcomes Measurement Information 
System (PROMIS) developed and tested its first wave of adult 
self-reported health outcome item banks: 2005-2008. J Clin 
Epidemiol. 2010;63:1179–1194.
23. Cherkin DC, Deyo RA, Street JH, Barlow W. Predicting poor 
outcomes for back pain seen in primary care using patients’ 
own criteria. Spine (Phila Pa 1976). 1996;21:2900–2907.
24. Childs JD, Fritz JM, Flynn TW, Irrgang JJ, Johnson KK, Ma-
jkowski GR, et al. A clinical prediction rule to identify patients 
with low back pain most likely to benefit from spinal manipula-
tion: a validation study. Ann Intern Med. 2004;141:920–928.
25. Chou R, Atlas SJ, Stanos SP, Rosenquist RW. Nonsurgical inter-
ventional therapies for low back pain: a review of the evidence 
for an American Pain Society clinical practice guideline. Spine 
(Phila Pa 1976). 2009;34:1078–1093.
26. Chou R, Deyo RA, Jarvik JG. Appropriate use of lumbar im-
aging for evaluation of low back pain. Radiol Clin North Am. 
2012;50:569–585.
27. Chou R, Huffman LH. Medications for acute and chronic low 
back pain: a review of the evidence for an American Pain Soci-
ety/American College of Physicians clinical practice guideline. 
Ann Intern Med. 2007;147:505–514.
28. Chou R, Huffman LH. Nonpharmacologic therapies for acute 
and chronic low back pain: a review of the evidence for an 
American Pain Society/American College of Physicians clinical 
practice guideline. Ann Intern Med. 2007;147:492–504.
29. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, 
Baisden J, et al. Interventional therapies, surgery, and interdis-
ciplinary rehabilitation for low back pain: an evidence-based 
clinical practice guideline from the American Pain Society. 
Spine (Phila Pa 1976). 2009;34:1066–1077.
30. Chou R, Shekelle P. Will this patient develop persistent dis-
abling low back pain? JAMA. 2010;303:1295–1302.
31. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief 
Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138.
32. Cook KF, Choi SW, Crane PK, Deyo RA, Johnson KL, 
Amtmann D. Letting the CAT out of the bag: comparing 
computer adaptive tests and an 11-item short form of the 
Roland-Morris Disability Questionnaire. Spine (Phila Pa 
1976). 2008;33:1378–1383.
33. Croft P, Dunn KM, Von Korff M. Chronic pain syndromes: you 
can’t have one without another. Pain. 2007;131:237–238.
referenCes
 1. Accessing PROMIS Short Form Instruments. Available at: 
http://www.assessmentcenter.net/PromisForms.aspx Accessed 
February 02, 2014.
 2. PROsetta Stone: Linking Patient-Reported Outcome Measures. 
Available at: http://www.prosettastone.org Accessed February 
02, 2014. 
 3. Relieving Pain in America: a Blueprint for Transforming 
Prevention, Care, Education, and Research. The National 
Academies Press; 2011.
 4. Abraham I, Killackey-Jones B. Lack of evidence-based research 
for idiopathic low back pain: the importance of a specific diag-
nosis. Arch Intern Med. 2002;162:1442–1444; discussion 1447.
 5. Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki 
D, et al. Development of a PROMIS item bank to measure pain 
interference. Pain. 2010;150:173–182.
 6. Apeldoorn AT, Bosmans JE, Ostelo RW, de Vet HC, van 
Tulder MW. Cost-effectiveness of a classification-based 
system for sub-acute and chronic low back pain. Eur Spine J. 
2012;21:1290–1300.
 7. Askew RL, Kim J, Chung H, Cook KF, Johnson KL, Amtmann 
D. Development of a crosswalk for pain interference measured 
by the BPI and PROMIS pain interference short form. Qual 
Life Res. 2013;22:2769–2776.
 8. Atlas SJ, Deyo RA, van den Ancker M, Singer DE, Keller RB, 
Patrick DL. The Maine-Seattle back questionnaire: a 12-item 
disability questionnaire for evaluating patients with lumbar 
sciatica or stenosis: results of a derivation and validation cohort 
analysis. Spine (Phila Pa 1976). 2003;28:1869–1876.
 9. Baliki MN, Petre B, Torbey S, Herrmann KM, Huang L, 
Schnitzer TJ, et al. Corticostriatal functional connectiv-
ity predicts transition to chronic back pain. Nat Neurosci. 
2012;15:1117–1119.
10. Barker KL, Shamley DR, Jackson D. Changes in the cross-
sectional area of multifidus and psoas in patients with unilateral 
back pain: the relationship to pain and disability. Spine (Phila 
Pa 1976). 2004;29:E515–519.
11. Battie MC, Niemelainen R, Gibbons LE, Dhillon S. Is level- 
and side-specific multifidus asymmetry a marker for lumbar 
disc pathology? Spine J. 2012;12:932–939.
12. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of beck 
depression inventories -IA and -II in psychiatric outpatients. J 
Pers Assess. 1996;67:588–597.
13. Beneciuk JM, Bishop MD, Fritz JM, Robinson ME, Asal 
NR, Nisenzon AN, et al. The STarT back screening tool and 
individual psychological measures: evaluation of prognostic 
capabilities for low back pain clinical outcomes in outpatient 
physical therapy settings. Phys Ther. 2013;93:321–333.
14. Beneck GJ, Kulig K. Multifidus atrophy is localized and bi-
lateral in active persons with chronic unilateral low back pain. 
Arch Phys Med Rehabil. 2012;93:300–306.
15. Bogduk N. On the definitions and physiology of back pain, 
referred pain, and radicular pain. Pain. 2009;147:17–19.
16. Bombardier C. Outcome assessments in the evaluation of 
treatment of spinal disorders: summary and general recom-
mendations. Spine (Phila Pa 1976). 2000;25:3100–3103.
17. Bombardier C, Evans CJ, Katz N, Mardekian J, Zlateva G, 
Simon LS. Further qualification of a therapeutic responder 
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
31
InternatIonal Journal of therapeutIc Massage and Bodywork—VoluMe 8, nuMBer 3, septeMBer 2015
51. Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, et al. 
Standardizing patient-reported outcomes assessment in cancer 
clinical trials: a patient-reported outcomes measurement infor-
mation system initiative. J Clin Oncol. 2007;25:5106–5112.
52. Genevay S, Atlas SJ, Katz JN. Variation in eligibility cri-
teria from studies of radiculopathy due to a herniated disc 
and of neurogenic claudication due to lumbar spinal ste-
nosis: a structured literature review. Spine (Phila Pa 1976). 
2010;35:803–811.
53. Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. De-
termination of moderate-to-severe postoperative pain on the 
numeric rating scale: a cut-off point analysis applying four 
different methods. Br J Anaesth. 2011;107:619–626.
54. Gusi N, del Pozo-Cruz B, Olivares PR, Hernandez-Mocholi 
M, Hill JC. The Spanish version of the “STarT Back Screen-
ing Tool” (SBST) in different subgroups. Aten Primaria. 
2011;43:356–361.
55. Hahn EA, Devellis RF, Bode RK, Garcia SF, Castel LD, Eisen 
SV, et al. Measuring social health in the patient-reported out-
comes measurement information system (PROMIS): item bank 
development and testing. Qual Life Res. 2010;19:1035–1044.
56. Hall H, McIntosh G, Boyle C. Effectiveness of a low back pain 
classification system. Spine J. 2009;9:648–657.
57. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster 
NE, et al. A primary care back pain screening tool: identify-
ing patient subgroups for initial treatment. Arthritis Rheum. 
2008;59:632–641.
58. Hill JC, Dunn KM, Main CJ, Hay EM. Subgrouping low back 
pain: a comparison of the STarT Back Tool with the Orebro 
Musculoskeletal Pain Screening Questionnaire. Eur J Pain. 
2010;14:83–89.
59. Hill JC, Vohora K, Dunn KM, Main CJ, Hay EM. Comparing 
the STarT back screening tool’s subgroup allocation of indi-
vidual patients with that of independent clinical experts. Clin 
J Pain. 2010;26:783–787.
60. Hill JC, Whitehurst DG, Lewis M, Bryan S, Dunn KM, Foster 
NE, et al. Comparison of stratified primary care management 
for low back pain with current best practice (STarT Back): a 
randomised controlled trial. Lancet. 2011;378:1560–1571.
61. Hoy D, Bain C, Williams G, March L, Brooks P, Blyth F, et al. 
A systematic review of the global prevalence of low back pain. 
Arthritis Rheum. 2012;64:2028–2037.
62. Hoy D, Brooks P, Blyth F, Buchbinder R. The epidemiol-
ogy of low back pain. Best Pract Res Clin Rheumatol. 
2010;24:769–781.
63. Hung M, Hon SD, Franklin JD, Kendall RW, Lawrence BD, 
Neese A, et al. Psychometric properties of the PROMIS physi-
cal function item bank in patients with spinal disorders. Spine 
(Phila Pa 1976). 2014;39:158–163.
64. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring 
health-related quality of life in rheumatoid arthritis: validity, 
responsiveness and reliability of EuroQol (EQ-5D). Br J Rheu-
matol. 1997;36:551–559.
65. Jensen MP KP: Self-report scales and procedures for assessing 
pain in adults. In: Turk DC, Editor. Handbook of Pain Assess-
ment. New York: Guilford Press; 2001: 15–34.
66. Jensen MP, Smith DG, Ehde DM, Robinsin LR. Pain site and the 
effects of amputation pain: further clarification of the meaning 
of mild, moderate, and severe pain. Pain. 2001;91:317–322.
34. Deyo RA. Diagnostic evaluation of LBP: reaching a specific di-
agnosis is often impossible. Arch Intern Med. 2002;162:1444–
1447; discussion 1447–1448.
35. Deyo RA, Battie M, Beurskens AJ, Bombardier C, Croft P, 
Koes B, et al. Outcome measures for low back pain research. 
A proposal for standardized use. Spine (Phila Pa 1976). 
1998;23:2003–2013.
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comor-
bidity index for use with ICD-9-CM administrative databases. 
J Clin Epidemiol. 1992;45:613–619.
37. Deyo RA, Mirza SK, Turner JA, Martin BI. Overtreating 
chronic back pain: time to back off? J Am Board Fam Med. 
2009;22:62–68.
38. Dunn KM, Croft PR, Main CJ, Von Korff M. A prognostic ap-
proach to defining chronic pain: replication in a UK primary 
care low back pain population. Pain. 2008;135:48–54.
39. Dunn KM VKM, Croft P: Defining chronic pain by prognosis. 
In: Hasenbring RA, Turk DC, Eds. From Acute to Chronic Back 
Pain: Risk Factors, Mechanisms, and Clinical Implications. 
New York: Oxford University Press; 2012: 21–40.
40. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jen-
sen MP, Katz NP, et al. Core outcome measures for chronic 
pain clinical trials: IMMPACT recommendations. Pain. 
2005;113:9–19.
41. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, 
Burke LB, Cowan P, et al. Interpreting the clinical importance 
of group differences in chronic pain clinical trials: IMMPACT 
recommendations. Pain. 2009;146:238–244.
42. Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, 
Peirce-Sandner S, et al. Development and initial validation of 
an expanded and revised version of the Short-form McGill Pain 
Questionnaire (SF-MPQ-2). Pain. 2009;144:35–42.
43. Edelen MO, Saliba D. Correspondence of verbal descriptor and 
numeric rating scales for pain intensity: an item response theory 
calibration. J Gerontol A Biol Sci Med Sci. 2010;65:778–785.
44. Fairbank J, Gwilym SE, France JC, Daffner SD, Dettori J, 
Hermsmeyer J, et al. The role of classification of chronic low 
back pain. Spine (Phila Pa 1976). 2011;36:S19–42.
45. Fairbank JC, Couper J, Davies JB, O’Brien JP. The Oswes-
try low back pain disability questionnaire. Physiotherapy. 
1980;66:271–273.
46. Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. 
Clinical importance of changes in chronic pain intensity 
measured on an 11-point numerical pain rating scale. Pain. 
2001;94:149–158.
47. Field J, Newell D. Relationship between STarT Back Screening 
Tool and prognosis for low back pain patients receiving spinal 
manipulative therapy. Chiropr Man Therap. 2012;20:17.
48. Friedman BW, Mulvey L, Davitt M, Choi H, Esses D, Bijur 
PE, et al. Predicting 7-day and 3-month functional outcomes 
after an ED visit for acute nontraumatic low back pain. Am J 
Emerg Med. 2012;30:1852–1859.
49. Fritz JM, Beneciuk JM, George SZ. Relationship between cat-
egorization with the STarT Back Screening Tool and prognosis 
for people receiving physical therapy for low back pain. Phys 
Ther. 2011;91:722–732.
50. Froud R, Eldridge S, Kovacs F, Breen A, Bolton J, Dunn K, et 
al. Reporting outcomes of back pain trials: a modified Delphi 
study. Eur J Pain. 2011;15:1068–1074.
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
32
InternatIonal Journal of therapeutIc Massage and Bodywork—VoluMe 8, nuMBer 3, septeMBer 2015
and emerging methods. Expert Rev Pharmacoecon Outcomes 
Res. 2011;11:163–169.
85. Morso L, Albert H, Kent P, Manniche C, Hill J. Translation 
and discriminative validation of the STarT Back Screening 
Tool into Danish. Eur Spine J. 2011;20:2166–2173.
86. Muller S, Thomas E, Dunn KM, Mallen CD. A prognostic 
approach to defining chronic pain across a range of musculo-
skeletal pain sites. Clin J Pain. 2013;29:411–416.
87. Negrini S, Zaina F. The chimera of low back pain etiology: a 
clinical rehabilitation perspective. Am J Phys Med Rehabil. 
2013;92:93–97.
88. Patrick DL, Deyo RA, Atlas SJ, Singer DE, Chapin A, Keller RB. 
Assessing health-related quality of life in patients with sciatica. 
Spine (Phila Pa 1976). 1995;20:1899–1908; discussion 1909.
89. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, 
Cella D. Item banks for measuring emotional distress from the 
Patient-Reported Outcomes Measurement Information System 
(PROMIS(R)): depression, anxiety, and anger. Assessment. 
2011;18:263–283.
90. Radloff LS. The CES-D scale: A self-report depression scale 
for research in general populations. Applied Psychological 
Measurement. 1977;1:385–401.
91. Rajaee SS, Bae HW, Kanim LE, Delamarter RB. Spinal fusion 
in the United States: analysis of trends from 1998 to 2008. Spine 
(Phila Pa 1976). 2012;37:67–76.
92. Revicki DA, Cook KF, Amtmann D, Harnam N, Chen WH, Keefe 
FJ. Exploratory and confirmatory factor analysis of the PROMIS 
pain quality item bank. Qual Life Res. 2014;23:245–255.
93. Rodriguez-Raecke R, Niemeier A, Ihle K, Ruether W, May A. 
Structural brain changes in chronic pain reflect probably neither 
damage nor atrophy. PLoS One. 2013;8:e54475.
94. Roland M, Morris R. A study of the natural history of back 
pain. Part I: development of a reliable and sensitive mea-
sure of disability in low-back pain. Spine (Phila Pa 1976). 
1983;8:141–144.
95. Rose M, Bjorner JB, Becker J, Fries JF, Ware JE. Evaluation 
of a preliminary physical function item bank supported the 
expected advantages of the Patient-Reported Outcomes Mea-
surement Information System (PROMIS). J Clin Epidemiol. 
2008;61:17–33.
96. Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic 
low back pain patients: relationship to patient characteristics 
and current adjustment. Pain. 1983;17:33–44.
97. Salovey PSW, Smith AF, Turk DC, Jobe JB, Willis GB. Re-
porting chronic pain episodes on health surveys. In: Statistics 
NCfH, Washington DC, 1992.
98. Sarazin M, de Souza LC, Lehericy S, Dubois B. Clinical and 
research diagnostic criteria for Alzheimer’s disease. Neuroim-
aging Clin N Am. 2012;22:23–32.
99. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, 
Goulet JP, et al. Diagnostic criteria for temporomandibular 
disorders (DC/TMD) for clinical and research applications: 
recommendations of the International RDC/TMD Consortium 
Network and Orofacial Pain Special Interest Group. J Oral 
Facial Pain Headache. 2014;28:6–27.
100. Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi 
Z, Fallatah S, Ware MA, et al. Effective treatment of chronic 
low back pain in humans reverses abnormal brain anatomy and 
function. J Neurosci. 2011;31:7540–7550.
67. Jones KR, Vojir CP, Hutt E, Fink R. Determining mild, moder-
ate, and severe pain equivalency across pain-intensity tools in 
nursing home residents. J Rehabil Res Dev. 2007;44:305–314.
68. Kapstad H, Hanestad BR, Langeland N, Rustoen T, Stavem K. 
Cutpoints for mild, moderate and severe pain in patients with 
osteoarthritis of the hip or knee ready for joint replacement 
surgery. BMC Musculoskelet Disord. 2008;9:55.
69. Keefe FJ WD, Smith SJ. Assessment of pain behaviors. In: 
Turk DC, Editor. Handbook of Pain Assessment. New York: 
Guilford Press; 2001:170–190.
70. Kenan K, Mack K, Paulozzi L. Trends in prescriptions for 
oxycodone and other commonly used opioids in the United 
States, 2000-2010. Open Med. 2012;6:e41–47.
71. Kerns RD, Haythornthwaite J, Rosenberg R, Southwick S, 
Giller EL, Jacob MC. The Pain Behavior Check List (PBCL): 
factor structure and psychometric properties. J Behav Med. 
1991;14:155–167.
72. Kim J, Chung H, Amtmann D, Revicki DA, Cook KF. Mea-
surement invariance of the PROMIS pain interference item 
bank across community and clinical samples. Qual Life Res. 
2013;22:501–507.
73. Kongsted A, Johannesen E, Leboeuf-Yde C. Feasibility of 
the STarT back screening tool in chiropractic clinics: a cross-
sectional study of patients with low back pain. Chiropr Man 
Therap. 2011;19:10.
74. Konstantinou K, Hider SL, Jordan JL, Lewis M, Dunn KM, 
Hay EM. The impact of low back-related leg pain on outcomes 
as compared with low back pain alone: a systematic review of 
the literature. Clin J Pain. 2013;29:644–654.
75. Kori S MR, Todd D. Kinesophobia: a new view of chronic pain 
behavior. Pain Management. 1990;35–43.
76. Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Suther-
land JM, et al. Development and initial validation of the PEG, 
a three-item scale assessing pain intensity and interference. J 
Gen Intern Med. 2009;24:733–738.
77. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity 
of a brief depression severity measure. J Gen Intern Med. 
2001;16:606–613.
78. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a 
new measure for evaluating the severity of somatic symptoms. 
Psychosom Med. 2002;64:258–266.
79. Loisel P, Vachon B, Lemaire J, Durand MJ, Poitras S, Stock 
S, et al. Discriminative and predictive validity assessment of 
the Quebec task force classification. Spine (Phila Pa 1976). 
2002;27:851–857.
80. Mallen CD, Peat G, Thomas E, Dunn KM, Croft PR. Prognostic 
factors for musculoskeletal pain in primary care: a systematic 
review. Br J Gen Pract. 2007;57:655–661.
81. Margolis RB, Tait RC, Krause SJ. A rating system for use with 
patient pain drawings. Pain. 1986;24:57–65.
82. Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales 
KH, Kosten TR, et al. Systematic review: opioid treatment for 
chronic back pain: prevalence, efficacy, and association with 
addiction. Ann Intern Med. 2007;146:116–127.
83. Martin BI, Deyo RA, Mirza SK, Turner JA, Comstock BA, 
Hollingworth W, et al. Expenditures and health status among 
adults with back and neck problems. JAMA. 2008;299:656–664.
84. McLeod LD, Coon CD, Martin SA, Fehnel SE, Hays RD. In-
terpreting patient-reported outcome results: US FDA guidance 
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
33
InternatIonal Journal of therapeutIc Massage and Bodywork—VoluMe 8, nuMBer 3, septeMBer 2015
116. Von Korff M, Shortreed SM, Saunders KW, Leresche L, Berlin 
JA, Stang P, et al. Comparison of back pain prognostic risk 
stratification item sets. J Pain. 2014;15:81–89.
117. Waddell G. 1987 Volvo award in clinical sciences. A new clini-
cal model for the treatment of low-back pain. Spine (Phila Pa 
1976). 1987;12:632–644.
118. Waddell G, Newton M, Henderson I, Somerville D, Main CJ. A 
Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of 
fear-avoidance beliefs in chronic low back pain and disability. 
Pain. 1993;52:157–168.
119. Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form 
Health Survey: construction of scales and preliminary tests of 
reliability and validity. Med Care. 1996;34:220–233.
120. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form 
health survey (SF-36). I. Conceptual framework and item 
selection. Med Care. 1992;30:473–483.
121. Weathers FWF. Psychometric properties of the PTSD Checklist 
(PCL–C, PCL–S, PCL–M, PCL–PR). In: Stamm BH, Editor. 
Measurement of Stress, Trauma, and Adaptation. Lutherville, 
MD: Sidran Foundation & Press; 1996:250–252.
122. Wideman TH, Hill JC, Main CJ, Lewis M, Sullivan MJ, Hay 
EM. Comparing the responsiveness of a brief, multidimensional 
risk screening tool for back pain to its unidimensional reference 
standards: the whole is greater than the sum of its parts. Pain. 
2012;153:2182–2191.
123. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important 
differences were estimated for six Patient-Reported Outcomes 
Measurement Information System-Cancer scales in advanced-
stage cancer patients. J Clin Epidemiol. 2011;64:507–516.
124. Zigler J, Delamarter R, Spivak JM, Linovitz RJ, Danielson GO, 
3rd, Haider TT, et al. Results of the prospective, randomized, 
multicenter Food and Drug Administration investigational 
device exemption study of the ProDisc-L total disc replacement 
versus circumferential fusion for the treatment of 1-level degen-
erative disc disease. Spine (Phila Pa 1976). 2007;32:1155–1162; 
discussion 1163.
125. Zigmond AS, Snaith RP. The hospital anxiety and depression 
scale. Acta Psychiatr Scand. 1983;67:361–370.
Corresponding author: Richard A. Deyo MD, 
MPH, Oregon Health and Science University, 3181 
SW Sam Jackson Park Rd., Mail Code FM, Portland, 
OR 97239, USA 
E-mail: deyor@ohsu.edu
101. Shah RV. Spine pain classification: the problem. Spine (Phila 
Pa 1976). 2012;37:1853–1855.
102. Simon LS, Evans C, Katz N, Bombardier C, West C, Robbins J, 
et al. Preliminary development of a responder index for chronic 
low back pain. J Rheumatol. 2007;34:1386–1391.
103. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure 
for assessing generalized anxiety disorder: the GAD-7. Arch 
Intern Med. 2006;166:1092–1097.
104. Spitzer WO, Abenhaim L, Dupuis M, Belanger AY, Bloch R, 
Bombardier C, et al. Scientific approach to the assessment and 
management of activity-related spinal disorders. A monograph 
for clinicians. Report of the Quebec Task Force on Spinal 
Disorders. Chapter 3: Diagnosis of the problem (the problem 
of diagnosis). Spine (Phila Pa 1976). 1987;12:S16–S21.
105. Stanton TR, Latimer J, Maher CG, Hancock MJ. A modified 
Delphi approach to standardize low back pain recurrence ter-
minology. Eur Spine J. 2011;20:744–752.
106. Stewart WF, Lipton RB, Simon D, Liberman J, Von Korff M. 
Validity of an illness severity measure for headache in a popula-
tion sample of migraine sufferers. Pain. 1999;79:291–301.
107. Sullivan MJB, Pivik J. The pain catastrophizing scale: 
development and validation. Psychological Assessment. 
1995;7:524–532.
108. Thomas E, Dunn KM, Mallen C, Peat G. A prognostic approach 
to defining chronic pain: application to knee pain in older adults. 
Pain. 2008;139:389–397.
109. Tracey I, Bushnell MC. How neuroimaging studies have 
challenged us to rethink: is chronic pain a disease? J Pain. 
2009;10:1113–1120.
110. Turner JA, Shortreed SM, Saunders KW, Leresche L, Berlin 
JA, Korff MV. Optimizing prediction of back pain outcomes. 
Pain. 2013;154:1391–1401.
111. Vickers AJ. The use of percentage change from baseline as 
an outcome in a controlled trial is statistically inefficient: a 
simulation study. BMC Med Res Methodol. 2001;1:6.
112. Von Korff M: Assessment of chronic pain in epidemiological 
and health services research: empirical cases and new direc-
tions. In: Turk DC, Editor. Handbook of Pain Assessment. New 
York: Guilford Press; 2011:455–473.
113. Von Korff M, Dunn KM. Chronic pain reconsidered. Pain. 
2008;138:267–276.
114. Von Korff M, Miglioretti DL. A prognostic approach to defining 
chronic pain. Pain. 2005;117:304–313.
115. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the 
severity of chronic pain. Pain. 1992;50:133–149.
DEYO: RESEARCH STANDARDS FOR CHRONIC LOW BACK PAIN
